LER_Orthotic_Management_CMT PDF

…We will achieve this vision through our extensive and focused drug development research initiative, STAR (Strategy to Accelerate Research). We know that we will soon be successful in finding treatments…

The_2018_CMTA_Report_35th_Anniversary_Edition

…or treatment-focused research through STAR in recent years, but the need remains to raise at least $10 million more to support our strategy to deliver treatments to our community. It’s…

2020_CMT_PFC_Pediatric_Neurology_transcript

…infantile form, typically fatal by two years of age, though there are milder forms that show up a little bit later. And we now have three treatments for this condition,…

2020_CMTA_PCF_Adult_Neurology_transcript

…with the various names and terminologies and concepts that goes with the diagnosis and ultimately the treatment of CMT. And for someone who’s been doing this for their whole adult…

LER_Orthotic_Management_CMT

…We will achieve this vision through our extensive and focused drug development research initiative, STAR (Strategy to Accelerate Research). We know that we will soon be successful in finding treatments…

The_2018_CMTA_Report_35th_Anniversary_Edition

…or treatment-focused research through STAR in recent years, but the need remains to raise at least $10 million more to support our strategy to deliver treatments to our community. It’s…

2021 CMTA Annual Report

…CMT respond to this treatment. 7 CMTA-STAR’S PORTFOLIO FOR DEMYELINATING CMTs: 1A, 1B, 1X (AND SOME 4s) The CMTA is taking an aggressive approach to developing treatments for the demyelinating…

2019_Fall_CMTA_Report

…of Type 2 breakthroughs on our way to treatments for CMT. Our CMT2 strategy covers virtually all Type 2s, including those with unknown genetic causes. Despite the diversity of genetic…

2020_Spring_CMTA_Report

…name of science. I am proud to have stepped forward in the effort to find a treatment for CMT. I am proud to have been a CMT lab rat. I…